Harmony Biosciences (HRMY) vs Prestige Consumer Healthcare (PBH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Harmony Biosciences (HRMY) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 50.4% versus a loss of 23.2%. Over five years, HRMY leads with a +2.2% price change compared with -17.4% for PBH. Harmony Biosciences is the larger company by market cap ($2.35 billion vs $2.28 billion), about 1.0 times the size.
On valuation, Harmony Biosciences trades at a lower forward P/E (5.8x vs 9.5x for Prestige Consumer Healthcare). Harmony Biosciences converts more of its revenue into profit, with a net margin of 18.3% versus 17.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRMY | PBH |
|---|---|---|
| Share price | $40.28 | $48.23 |
| Market cap | $2.35B | $2.28B |
| 1-day change | +1.72% | +0.75% |
| YTD return | +7.64% | -21.82% |
| 1-year return | +50.41% | -23.19% |
| 5-year return | +2.23% | -17.44% |
| P/E ratio (TTM) | 12.99 | 13.51 |
| Forward P/E | 5.75 | 9.49 |
| EPS (TTM) | $3.10 | $3.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $868.45M | $1.09B |
| Revenue growth (YoY) | +21.51% | -4.31% |
| Net income (latest FY) | $158.69M | $190.30M |
| Gross margin | 77.16% | 54.71% |
| Operating margin | 24.00% | 28.42% |
| Net margin | 18.27% | 17.48% |
| 52-week high | $43.49 | $71.07 |
| 52-week low | $25.52 | $42.62 |
| Distance from 52-week high | -7.38% | -32.14% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +18.27% | +40.58% |
| Average volume | 896.11K | 547.31K |
| Shares outstanding | 58.24M | 47.37M |
| Employees | 293 | 890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HRMY has outperformed PBH by 73.6 percentage points over the past year.
- Harmony Biosciences grew revenue faster in its latest fiscal year (+21.51% vs -4.31%).
About Harmony Biosciences
HRMY stock →Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Prestige Consumer Healthcare
PBH stock →Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees
HRMY vs PBH FAQ
Which is bigger, Harmony Biosciences or Prestige Consumer Healthcare?
Harmony Biosciences (HRMY) is larger, with a market capitalization of $2.35B compared with $2.28B for Prestige Consumer Healthcare (PBH).
Which stock has performed better over the past year, HRMY or PBH?
HRMY returned +50.41% over the past 12 months, compared with -23.19% for PBH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HRMY or PBH?
HRMY has the lower trailing P/E at 13.0, versus 13.5 for PBH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Harmony Biosciences and Prestige Consumer Healthcare in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.